177Lu-PSMA-I&T is a radiolabeled peptide developed by the Technical University Munich. PSMAI&T was labeled also with 68Ga and 111In for respectively PET and SPECT imaging (but also radio-guided surgery), hence creating a PSMA-probes platform.
177Lu-PSMA-I&T is a drug under development as a therapy for metastatic castration-resistant prostate cancer. First clinical data show a nice profile, similar to 177Lu-PSMA-617 and with much less side-effects as the ones observed with 131I-PSMA-11. 177Lu-PSMA-I&T has completed a phase I trial which was published in January 2016. First data on 56 patients proved the drug to be safe and effective in end stage progressive mCRPC with appropriate selection of patients with 68Ga-PSMA-11. This molecule continues to be developed by academic groups, in particular in China, as a potential alternative to 177Lu-PSMA-617.
Leading Emitter: beta electrons (β–)